<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Lab Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Lab Med</journal-id>
      <journal-id journal-id-type="publisher-id">ALM</journal-id>
      <journal-title-group>
        <journal-title>Annals of Laboratory Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2234-3806</issn>
      <issn pub-type="epub">2234-3814</issn>
      <publisher>
        <publisher-name>The Korean Society for Laboratory Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26354360</article-id>
      <article-id pub-id-type="pmc">4579116</article-id>
      <article-id pub-id-type="doi">10.3343/alm.2015.35.6.660</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
          <subj-group subj-group-type="heading">
            <subject>Diagnostic Immunology</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Anti-Rods and Rings Autoantibodies in a Patient With Hepatitis C Virus Infection</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Choi</surname>
            <given-names>Kyung Ho</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lim</surname>
            <given-names>Young Ae</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Think-You</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jearn</surname>
            <given-names>La-He</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baik</surname>
            <given-names>Sae Yun</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cho</surname>
            <given-names>Sung Won</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jeong</surname>
            <given-names>Eunju</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Laboratory Medicine, Ajou University School of Medicine, Suwon, Korea.</aff>
      <aff id="A2"><label>2</label>Department of Laboratory Medicine, Hanyang University School of Medicine, Seoul, Korea.</aff>
      <aff id="A3"><label>3</label>Green Cross Laboratories, Yongin, Korea.</aff>
      <aff id="A4"><label>4</label>Department of Internal Medicine, Ajou University School of Medicine, Suwon, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: Young Ae Lim. Department of Laboratory Medicine, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-gu, Suwon 16499, Korea. Tel: +82-31-219-5786, Fax: +82-31-219-5778, <email>limyoung@ajou.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>01</day>
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <volume>35</volume>
      <issue>6</issue>
      <fpage>660</fpage>
      <lpage>662</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>1</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>08</day>
          <month>5</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>7</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Korean Society for Laboratory Medicine.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor</p>
    <p>The fluorescent antinuclear antibody (FANA) test is widely used for the detection of systemic autoantibodies. Moreover, the fluorescent patterns seen with the FANA test have specific clinical significance [<xref rid="B1" ref-type="bibr">1</xref><xref rid="B2" ref-type="bibr">2</xref>]. We recently observed an unfamiliar FANA pattern with several small cytoplasmic rod and ring immunofluorescence known as anti-rods and rings (RR) autoantibodies-the first instance in Korea-in a patient with hepatitis C virus (HCV) infection who received combined interferon (IFN) and ribavirin treatment [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref>].</p>
    <p>A 69-yr-old man was admitted to Ajou university hospital in Korea in July 2014 for jaundice due to liver cirrhosis. On admission, his condition worsened owing to hepatic failure. He had been diagnosed as having HCV infection, hypertension, and type 2 diabetes in 2001. He refused medical care until 2009, when he received treatment with IFN and ribavirin for one year. The treatment was discontinued because of ineffectiveness. There was no other history of supportive treatment, including herbal medication.</p>
    <p>On admission, the patient developed sudden jaundice with the following laboratory results: total bilirubin, 21 mg/dL; direct bilirubin, 15.0 mg/dL; ALT, 78 U/L; and AST, 265 U/L. As there were no previous FANA test data available, the physician requested a FANA test to rule out autoimmune hepatitis as the cause of hepatic failure [<xref rid="B7" ref-type="bibr">7</xref>]. The FANA test was performed by using the HEPANA test with HEp-2 cells (Medical &amp; Biological Laboratories Co., Ltd., Nagoya, Japan) and was read with a Zeiss Axio Imager A1 (Carl Zeiss Inc., Germany).</p>
    <p>A novel finding on the FANA test included several small cytoplasmic RR immunofluorescences (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). The result was reproducible with a titer of 1:640. Experts at another laboratory confirmed the pattern as anti-RR autoantibodies by using an autoimmune target (AIT) test (ImmunoThink Co., Seoul, Korea). Other reagents, such as HEp-2 ANA slides (INOVA Diagnostics, San Diego, CA, USA) also showed the RR pattern [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref>]. However, Kallestad HEp-2 cell line substrate (Bio-Rad Laboratories, Hercules, CA, USA) showed other cytoplasmic patterns, such as autoantibodies recognizing mitotic spindle apparatus-related antigens, instead of the RR pattern (<xref ref-type="fig" rid="F1">Fig. 1B</xref>). This discrepancy may be due to differences in the conditions used for particular tissue cultures and the fixation of HEp-2 cells. Therefore, all commercial HEp-2 slides may not be reactive to anti-RR autoantibodies [<xref rid="B6" ref-type="bibr">6</xref><xref rid="B8" ref-type="bibr">8</xref>].</p>
    <p>The patient developed acute renal failure likely owing to hepatorenal syndrome at admission and died on day 17 post-admission despite supportive treatment.</p>
    <p>There have been several reports about the incidence of the anti-RR pattern with hepatitis C and other illnesses. It is present in approximately 30% of the patients with chronic hepatitis C treated with IFN-ribavirin [<xref rid="B7" ref-type="bibr">7</xref>], 14.1% with hepatitis C, and 3.4% with hepatitis B but has not been observed in patients without any form of viral hepatitis [<xref rid="B8" ref-type="bibr">8</xref>]. High anti-RR autoantibody titers occur in patients with no response or relapsers [<xref rid="B3" ref-type="bibr">3</xref>], although some studies found no association between anti-RR titer and treatment response [<xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref>]. The patient's anti-RR titer was 1:640, which was high according to earlier reports [<xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref>]. The patient did not respond to combination IFN and ribavirin therapy.</p>
    <p>Anti-RR autoantibodies are reportedly detected more often in relapsers and non-responders than in sustained virological responders defined as having undetectable HCV RNA 24 weeks post-therapy [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref>]. The viral load of the present patient, 196,254 copies/mL (72,687 IU/mL), exceeded the category limits of high viral load [<xref rid="B7" ref-type="bibr">7</xref>]. We detected no hepatitis B virus co-infection or other autoantibodies, including anti-mitochondrial antibody or anti-smooth muscle antibody. This patient's treatment with IFN and ribavirin was discontinued after a year owing to lack of effectiveness; hence, the patient appeared to be a non-responder [<xref rid="B7" ref-type="bibr">7</xref>].</p>
    <p>We did not analyze the target antigens of anti-RR autoantibodies; several studies have reported that the target antigens of anti-RR autoantibodies are inosine monophosphate dehydrogenase 2 (IMPDH2), cytidine triphosphate synthase 1 (CTPS1), or both [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref><xref rid="B8" ref-type="bibr">8</xref>]. These enzymes, which normally mask epitopes that might participate in RR formation, are inhibited by IFN and ribavirin treatment, which induces structural modifications that make the epitopes accessible to the immune system [<xref rid="B5" ref-type="bibr">5</xref><xref rid="B8" ref-type="bibr">8</xref>]. Other potential target antigens, including Myc-associated zinc finger protein (MAZI), have also been reported and must be confirmed [<xref rid="B6" ref-type="bibr">6</xref>].</p>
    <p>Anti-RR autoantibodies can easily be overlooked if clinical pathologists ignore specific FANA patterns; therefore, FANA patterns require cautious interpretation. The anti-RR autoantibody pattern should also be distinguished from other cytoplasmic patterns and reported as the cytoplasmic RR pattern. Clinical information on patient history and present illness is helpful in the interpretation of unusual or unfamiliar FANA patterns.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p><bold>Authors' Disclosures of Potential Conflicts of Interest:</bold> No potential conflicts of interest relevant to this article were reported.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vermeersch</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bossuyt</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Prevalence and clinical significance of rare antinuclear antibody patterns</article-title>
          <source>Autoimmun Rev</source>
          <year>2013</year>
          <volume>12</volume>
          <fpage>998</fpage>
          <lpage>1003</lpage>
          <pub-id pub-id-type="pmid">23583982</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liberal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mieli-Vergani</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vergani</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Clinical significance of autoantibodies in autoimmune hepatitis</article-title>
          <source>J Autoimmun</source>
          <year>2013</year>
          <volume>46</volume>
          <fpage>17</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="pmid">24016388</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carcamo</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Ceribelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Calise</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Krueger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Daves</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients</article-title>
          <source>J Clin Immunol</source>
          <year>2013</year>
          <volume>33</volume>
          <fpage>420</fpage>
          <lpage>426</lpage>
          <pub-id pub-id-type="pmid">23100146</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Covini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Carcamo</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Bredi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>von M&#xFC;hlen</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Colombo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>EK</given-names>
            </name>
          </person-group>
          <article-title>Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C</article-title>
          <source>Antivir Ther</source>
          <year>2012</year>
          <volume>17</volume>
          <fpage>805</fpage>
          <lpage>811</lpage>
          <pub-id pub-id-type="pmid">22293655</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carcamo</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Satoh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kasahara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Terada</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hamazaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells</article-title>
          <source>PLoS One</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>e29690</fpage>
          <pub-id pub-id-type="pmid">22220215</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stinton</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Coffin</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Fritzler</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection</article-title>
          <source>BMC Gastroenterol</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>50</fpage>
          <pub-id pub-id-type="pmid">23506439</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Novembrino</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Aghemo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ferraris Fusarini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Maiavacca</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Matinato</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lunghi</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients</article-title>
          <source>J Viral Hepat</source>
          <year>2014</year>
          <volume>21</volume>
          <fpage>944</fpage>
          <lpage>949</lpage>
          <pub-id pub-id-type="pmid">25040504</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keppeke</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Nunes</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ferraz</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Granato</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Andrade</surname>
              <given-names>LE</given-names>
            </name>
          </person-group>
          <article-title>Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-&#x3B1;</article-title>
          <source>PLoS One</source>
          <year>2012</year>
          <volume>7</volume>
          <fpage>e45392</fpage>
          <pub-id pub-id-type="pmid">23028980</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <title>(A) Cytoplasmic rods and rings of HEp-2 cells with FITC-conjugated goat anti-human immunoglobins (Medical &amp; Biological Laboratories Co., Ltd., Nagoya, Japan) in sera from the patient with hepatitis C virus infection (&#xD7;200). (B) Cytoplasmic pattern (autoantibodies recognizing mitotic spindle apparatus-related antigens) observed with Kallestad HEp-2 cell line substrate (Bio-Rad Laboratories, Hercules, CA, USA) in sera from the patient with hepatitis C virus infection (&#xD7;200).</title>
      </caption>
      <graphic xlink:href="alm-35-660-g001"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
